Johnson & Johnson’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History

Johnson & Johnson’s Portfolio PHAS Stock Details PHAS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-1,607,044	Closed	-$283K	–	23
2022 Q3	$283K	Hold	1,607,044	–	–	0.08%	18
2022 Q2	$964K	Hold	1,607,044	–	–	0.25%	18
2022 Q1	$2.12M	Hold	1,607,044	–	–	0.4%	16
2021 Q4	$4.19M	Hold	1,607,044	–	–	0.48%	14
2021 Q3	$5M	Buy	+1,607,044	New	+$5.36M	0.44%	15

Other funds holding PHAS

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

HLA

Hamilton Lane Advisors Conshohocken, Pennsylvania $149M AUM 14.17% 1-Year Est. Return

IIA

IPG Investment Advisors San Diego, California $582M AUM 33.22% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Johnson & Johnson's PHAS Position: Q4 2022 in Review

Johnson & Johnson sold out of PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) in Q4 2022, closing a stake of 1,607,044 shares — an estimated $283K sold.

Johnson & Johnson first reported a position in PHAS in Q3 2021 and held it in 5 quarters. The position peaked at $5M in Q3 2021. 5 funds tracked by Wall St. Rank hold PHAS as of Q4 2022.

Johnson & Johnson reported no remaining PhaseBio Pharmaceuticals, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Johnson & Johnson sold 1,607,044 PhaseBio Pharmaceuticals, Inc. Common Stock shares in Q4 2022, an estimated $283K.
Johnson & Johnson first reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock in Q3 2021 and held it in 5 quarters.
Johnson & Johnson's PhaseBio Pharmaceuticals, Inc. Common Stock position peaked at $5M in Q3 2021.
5 funds tracked by Wall St. Rank held PhaseBio Pharmaceuticals, Inc. Common Stock as of Q4 2022.

Based on Johnson & Johnson's 13F filing for Q4 2022, filed 9 Feb 2023.